Bristol Myers’ Estimates Boosted at Citigroup (BMY)

By Staff,

Shutterstock photo

Pharmaceutical products maker Bristol Myers Squibb Co. ( BMY ) on Monday saw its earnings estimates raised by analysts at Citigroup.

The firm said it lifted its estimates for BMY through 2012, citing strong currency trends that will positively impact the company's bottom line. Citigroup also noted that new product launches will help add to earnings.

Bristol-Myers shares were unchanged in premarket trading Monday.

The Bottom Line
We have been recommending shares of Bristol-Myers ( BMY ) since Aug.25, 2009, when the stock was trading at $22.58. The company has a 4.53% dividend yield, based on Friday's closing stock price of $29.12.

Bristol Myers Squibb Co. ( BMY ) is a "Highly Recommended" dividend stock, holding a DARS™ Rating of 3.8 out of 5 stars.

Be sure to visit our complete recommended list of the Best Dividend Stocks , as well as a detailed explanation of our ratings system here .

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Created by

This article appears in: Investing Stocks
Referenced Stocks: BMY

More from

Follow on:

Find a Credit Card

Select a credit card product by:
Select an offer:
Data Provided by